Sarcoidosis Associated Pulmonary Hypertension

Size: px
Start display at page:

Download "Sarcoidosis Associated Pulmonary Hypertension"

Transcription

1 Sarcoidosis Associated Pulmonary Hypertension H. James Ford MD Assistant Professor of Medicine Director, Pulmonary Hypertension Program University of North Carolina at Chapel Hill

2 Disclosures Consultant for Actelion and United Therapeutics Research grants from Actelion, United Therapeutics, and Gilead.

3 Case 40 y/o female with biopsy proven sarcoidosis (EBUS of mediastinal node) PFTs normal spirometry, normal lung volumes, DLCO 55% predicted. Having progressive dyspnea on exertion, LE edema. Echo suggests PH and RV dysfunction. CXR with clear lung fields, +hilar and med lymphadenopathy. History of sarcoid liver disease as well with bilirubin 3.1 at baseline and evidence of gastric varices on recent imaging.

4 Case contd. RHC done: RA 9, mean PA 52, PAWP 8, CO 4.6 L/min, CI 2.7, PVR 9.6 WU Does this patient have: 1) Sarcoidosis and Idiopathic PAH (WHO Grp 1) 2) Sarcoidosis associated PH (WHO Grp 5) 3) Portopulmonary Hypertension and Sarcoidosis (WHO Grp 1) 4) Your guess is as good as mine

5 Sarcoidosis Sarcoidosis is a disease characterized by noncaseating granulomatous tissue inflammation. Can affect nearly any organ system (CNS, skin, myocardium, liver, kidney, lung, eye). The lung is the most commonly affected organ. Demographics Northern European Caucasians, and African-Americans (large population in southeastern U.S., particularly in the Carolinas) Thomas KW, Hunninghake GW. JAMA. 2003;289(24):3300.

6 Sarcoidosis and the Lung Manifestations in the lung can include: Lymphadenopaty Inflammatory (ground glass) process Fibrotic lung disease with associated sequelae Cyst/cavity formation Traction bronchiectasis Obstructive airways disease (endobronchial sarcoid) Pulmonary Hypertension Secondary PH Granulomatous vascular lesions PAH? Immunomodulatory therapy is the standard of care.

7 Stages of Sarcoidosis stage I: hilar or mediastinal nodal enlargement only stage III: parenchymal disease only stage II: nodal enlargement and parenchymal disease stage IV: end-stage lung (pulmonary fibrosis)

8 How Does Sarcoid Fit in the Classification of PH?(2008 Dana Point) 5. Pulmonary hypertension with unclear multifactorial mechanisms 5.1. Hematologic disorders: myeloproliferative disorders, splenectomy 5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis, neurofibromatosis, vasculitis 5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis

9 Pulmonary Hypertension in Sarcoidosis Can be present with varying degrees of restrictive and obstructive lung disease. Difficulty lies in determining the relative contributor of PH and parenchymal or obstructive lung disease to clinical presentation. How much PAH vs. WHO Group 3 or 2 disease? Phenomenon of disproportionate PVD Increased levels of endothelin (ET)-1 in plasma and bronchoalveolar lavage of some sarcoid patients. This suggests ET-1 may be driving pulmonary fibrosis and sarcoidosis-associated pulmonary hypertension. PVOD can also be seen in sarcoid. Baughman, B. Arthritis Res Ther. 2007; 9(Suppl 2): S8.

10 The Importance of RHC in Sarcoid Retrospective analysis of 130 patients with sarcoid and persistent DOE despite immunomodulator therapy. Underwent RHC at least 18 months prior to analysis 50 pts with PH and PCWP < 15 mm Hg 20 pts with PH and PCWP > 15 mmhg Hazard ratio for dying for PH with PCWP < 15 mmg vs PH with PCWP > 15 was % of patients with PH had LV dysfunction (PCWP > 15 mmhg) Baughman, RP et al Chest Nov;138(5):

11 Treatment of SAPH Two-center experience with 22 patients Retrospective (JHU and Inova Fairfax) Patients with PAH hemodynamics Any PAH therapy in context of sarcoid Median follow up = 11 months Improvement in 6MWD related to baseline FVC. 12 patients with hemodynamic data showed improvement in mpap and PVR. Barnett, CF et al. CHEST.June 2009;135(6):

12 Treatment of SAPH A few early small case series and case reports suggest bosentan is efficacious in select sarcoid patients. Sharma et al: 1 patient treated with bosentan, improved 6MWD and functional class. Foley et al: 1 patient treated with bosentan, improved functional class and hemodynamics. Baughman: 4 patients treated with bosentan with improved hemodynamics. Pitsiou: 1 patient treated with bosentan with functional class and 6MWT improvement. Sharma S, Kashour T, Philipp R. Tex Heart Inst J. 2005;32(3): Foley, RJ. Respiration 2008;75: Baughman, B. Arthritis Res Ther. 2007; 9(Suppl 2): S8. Pitsiou et al. Ther Adv Respir Dis (2009) 3(3).

13 Ambrisentan for Sarcoid Associated PH 24 week prospective, open-label trial of ambrisentan in sarcoid patients with PH Primary endpoint = 6 MWD Secondary endpoints = modified Borg scale, serum brain naturetic peptide, diffusing capacity, and quality of life as measured by the Short Form-36 5 mg daily ambrisentan for 4 weeks, followed by 10 mg daily ambrisentan for 20 weeks. M.A. Judson et al. SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2011; 28;

14 Ambrisentan for Sarcoid Associated PH Inclusion criteria Biopsy proven sarcoidosis MPAP > 25 mmhg at rest or > 30 mmhg with exercise by RHC within 1 year Pulmonary capillary wedge pressure 15 mmhg PVR >3.0 Woods units Forced vital capacity (FVC) >40% WHO functional class II or III Stable sarcoidosis treatment regimen for three months prior to entry into study 6 minute walk distance between meters Stable dose of antihypertensive medications. No other PAH meds. Exclusion Criteria Exercise limitation related to a noncardiopulmonary reason (e.g. arthritis) Severe systemic hypertension > 170/95 Patients with congestive heart failure (left ventricular dysfunction) or primary right ventricular dysfunction Anticipation by the investigator for escalation in sarcoidosis treatment during the course of the study Pulmonary hypertension related to etiology other than sarcoidosis (i.e. HIV, scleroderma, etc.) Use within 1 month of an endothelin receptor antagonists (bosentan, sitaxsentan). WHO functional class IV status Significant left ventricular dysfunction Significant liver dysfunction not due to sarcoidosis. Patients with severe other organ disease felt by investigators to impact on survival during the course of the study. Pregnant females

15 Ambrisentan for Sarcoid Associated PH 21 patients enrolled. MPAP (mmhg): CO (L/min) PVR (Woods Units): No change in 6MWD (mean change between week 0 and 24: 9.8 ± 54.6 meters, p: NS) No significant change in secondary endpoints. High dropout rate (11/21; 52%) 10/21 that completed study: Improvement in WHO functional class --NS Improvement in HRQOL as per SF 36--NS

16 Bosentan for SAPH 16 week, double-blind, placebo controlled trial of bosentan in SAPH (2:1) 35 patients completed study (23 active treatment, 12 placebo) No change in 6 MWD Significant improvement in hemodynamics Baughman et al

17 Bosentan for SAPH Baughman et al

18 Prostacyclins for SAPH One case series published from BU. Retrospective followed 5 patients on epoprostenol for mean of 29 months. Mild to moderate restrictive lung disease Most with severe DLCO reduction Fisher et al. CHEST.June 2009;135(6):

19 Prostacyclins for SAPH Long term outcomes Mean dose epo = 55 ng/kg/min Fisher et al. CHEST.June 2009;135(6):

20 Iloprost for SAPH Iloprost is an inhaled prostacyclin Theoretically less risk of increasing v/q mismatch. Open-label, prospective study, 16 weeks of iloprost therapy. Pre and post RHC, 6MWD, SGRQ 22 patients with SAPH enrolled, 15 completed (cough and compliance) 6 pts with 20% or greater decrease in PVR Significant improvement in SGRQ score Baughmand RP et al. Sarcoidosis Vasc Diffuse Lung Dis Jul;26(2):

21 PDE-5 inhibitors for SAPH Single center, retrospective study 25 patients with stage 4 sarcoid referred for transplant. 79% had PH on RHC (mpap > 25 mmhg) Sildenafil administered over median of 4 months duration. Repeat RHC improvements in mpap, PVR, and CO/CI. No consistent changes in 6MWD. Milman et al. J Heart Lung Tsplt Mar;27(3):

22 Tadalafil for SAPH 24 week prospective, open-label, two-center trial of tadalafil in sarcoid patients with PH Primary endpoint = 6 MWD Secondary endpoints = modified Borg scale, serum brain naturetic peptide, diffusing capacity, and quality of life as measured by the Short Form mg daily tadalafil for 4 weeks, followed by 40 mg daily for 20 weeks. Inclusion and Exclusion Criteria same as ambrisentan study

23 Tadalafil for SAPH 12 patients enrolled. MPAP (mmhg): (25-49) PAWP (mmhg): 10.3 ± 3.6 (3-15) PVR (Woods Units): No change in 6MWD (mean change between week 0 and 24: NS) No significant change in secondary endpoints. High dropout rate (5/12; 42%)

24 PH in the Setting of Lung Disease Underlying Lung Disease COPD with FEV1 60% predicted IPF with FVC 70% predicted mpap < 25 mmhg 25 mpap < 35 mmhg No PH No PAH tx recommended Meets criteria for IPAH PAH treatment guidelines may apply mpap > 35 mmhg Meets criteria for IPAH PAH treatment guidelines may apply Minimal parenchymal or airway abnl on CT COPD with FEV1 < 60% predicted IPF with FVC < 70% predicted Combined pulm fibrosis and emphysema on CT No PH No PAH tx recommended PH-COPD, PH-IPF, PH- CPFE No data support treatment according to PAH tx guidelines Severe PH-COPD, PH- IPF, PH-CPFE Refer to center with expertise in both PH and chronic lung disease Potential use of PAH tx as a bridge to LT in end stage disease

25 Conclusions Sarcoidosis associated PH remains a challenge to define and treat. Some patients exhibit clearly disproportionate hemodynamic perturbations, while most have concomitant moderate lung disease and PVD. There is a paucity of data regarding the treatment approach to these patients. Larger, controlled trials needed to determine the broader utility of PAH therapies in SAPH.

PULMONARY HYPERTENSION. Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana

PULMONARY HYPERTENSION. Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana PULMONARY HYPERTENSION Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana What is Pulmonary Hypertension? What is normal? Pulmonary artery systolic pressure

More information

Riociguat Clinical Trial Program

Riociguat Clinical Trial Program Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension

More information

ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY

ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY Contents ELIGIBILITY CRITERIA FOR INITIATION OF PULMONARY ARTERIAL HYPERTENSION THERAPY... 2 Initial Application for Funding of Pulmonary

More information

FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C

FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR in Combination with an ERA and/or a PDE-5 Inhibitor

More information

PAH in. Registry to Evaluate Early and Long-Term PAH Disease Management

PAH in. Registry to Evaluate Early and Long-Term PAH Disease Management PAH in Registry to Evaluate Early and Long-Term PAH Disease Management Ioana R. Preston, MD Co-Director, Pulmonary Hypertension Center Tufts Medical Center, Boston, MA Background What is REVEAL? Multi-center,

More information

Pulmonary Arterial Hypertension. Matt Hegewald, MD FCCP St Charles Medical Center Intermountain Medical Center University of Utah

Pulmonary Arterial Hypertension. Matt Hegewald, MD FCCP St Charles Medical Center Intermountain Medical Center University of Utah Pulmonary Arterial Hypertension Matt Hegewald, MD FCCP St Charles Medical Center Intermountain Medical Center University of Utah Intermountain Pulmonary Arterial Hypertension Program Outline Causes of

More information

Pulmonary Artery Hypertension

Pulmonary Artery Hypertension Pulmonary Artery Hypertension Janet M. Pinson, RN, MSN, ACNP Maureen P. Flattery, RN, MS, ANP Virginia Commonwealth University Health System Richmond, VA Pulmonary artery hypertension (PAH) is defined

More information

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University

More information

Idiopathic Pulmonary Fibrosis (IPF) Research

Idiopathic Pulmonary Fibrosis (IPF) Research Idiopathic Pulmonary Fibrosis (IPF): Why Early Referral is Critical Even if Your Patient is Not Eligible for a Clinical Trial Idiopathic Pulmonary Fibrosis (IPF) Research Management of IPF requires a confident

More information

Pulmonary Hypertension in Sickle Cell Disease. Jorge Ramos Hematology Fellows Conference June 28, 2013

Pulmonary Hypertension in Sickle Cell Disease. Jorge Ramos Hematology Fellows Conference June 28, 2013 Pulmonary Hypertension in Sickle Cell Disease Jorge Ramos Hematology Fellows Conference June 28, 2013 Patient Presentation 28F with SCD, genotype SS. Presented to UWMC ER with 1 month progressive DOE and

More information

PULMONARY ARTERIAL HYPERTENSION AGENTS

PULMONARY ARTERIAL HYPERTENSION AGENTS Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Revatio Sildenafil citrate Calendar Year Adcirca Tadalafil Calendar Year Letairis Ambrisentan

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium sildenafil citrate 20mg tablets (Revatio ) No. (235/06) Pfizer New indication 6 January 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Remit / Appraisal objective: Final scope To appraise the clinical and cost effectiveness of

More information

Hope in 2011 Clinical Advances Where is the road taking us?

Hope in 2011 Clinical Advances Where is the road taking us? Hope in 2011 Clinical Advances Where is the road taking us? Richard Channick, MD Arlene Schiro, NP Disclosures Arlene Schiro no relevant financial and/or commercial relationships to disclose Hope is like

More information

2. Background This drug had not previously been considered by the PBAC.

2. Background This drug had not previously been considered by the PBAC. PUBLIC SUMMARY DOCUMENT Product: Ambrisentan, tablets, 5 mg and 10 mg, Volibris Sponsor: GlaxoSmithKline Australia Pty Ltd Date of PBAC Consideration: July 2009 1. Purpose of Application The submission

More information

Target therapies for the treatment of pulmonary arterial hypertension in Adults

Target therapies for the treatment of pulmonary arterial hypertension in Adults Paper K2 National Specialised Commissioning Group Commissioning Policy Target therapies for the treatment of pulmonary arterial hypertension in Adults POLICY PUBLISHED: 1 JULY 2008 POLICY REVISED: 14 JANUARY

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Pulmonary Hypertension, Drug Management File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pulmonary_hypertension_drug_management 06/1998 3/2015 3/2016 3/2015

More information

Pulmonal hypertensjon. Arne K. Andreassen Kardiologisk avdeling Oslo Universitetssykehus Rikshospitalet

Pulmonal hypertensjon. Arne K. Andreassen Kardiologisk avdeling Oslo Universitetssykehus Rikshospitalet Pulmonal hypertensjon Arne K. Andreassen Kardiologisk avdeling Oslo Universitetssykehus Rikshospitalet Clinical classification of pulmonary hypertension 1. Pulmonary arterial hypertension (PAH) 2. Pulmonary

More information

Pulmonary Arterial Hypertension: Assessment of disease s severity

Pulmonary Arterial Hypertension: Assessment of disease s severity Pulmonary Arterial Hypertension: Assessment of disease s severity Carmine Dario Vizza Dept. Cardiovascular and Respiratory Diseases La Sapienza University of Rome e-mail : dario.vizza@uniroma1.it Pulmonary

More information

PAH. Salman Bin AbdulAziz University College Of Pharmacy 22/01/35

PAH. Salman Bin AbdulAziz University College Of Pharmacy 22/01/35 Salman Bin AbdulAziz University College Of Pharmacy PAH Therapeutics II PHCL 430 Ahmed A AlAmer PharmD R.W. is a 38-year-old obese woman who presents with increasing symptoms of fatigue and shortness of

More information

Pulmonary Arterial Hypertension: Review and Updates. Is it Primary vs Secondary Pulmonary Hypertension? No!! Dated Nomenclature. Veronica Franco, MD

Pulmonary Arterial Hypertension: Review and Updates. Is it Primary vs Secondary Pulmonary Hypertension? No!! Dated Nomenclature. Veronica Franco, MD Pulmonary Arterial Hypertension: Review and Updates Veronica Franco, MD Section of Pulmonary Hypertension Section of Heart Failure and Transplantation Ohio State University Is it Primary vs Secondary Pulmonary

More information

Acknowledgements. PAH in Children: Natural History. The Sildenafil Saga

Acknowledgements. PAH in Children: Natural History. The Sildenafil Saga The Sildenafil Saga David L. Wessel, MD Executive Vice President Chief Medical Officer Ikaria Distinguished Professor of Critical Care Children s National Medical Center Washington, DC, USA Acknowledgements

More information

Pharmacy Policy Bulletin

Pharmacy Policy Bulletin Pharmacy Policy Bulletin Title: Policy #: Pulmonary Arterial Hypertensive (PAH) agents Rx.01.83 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product

More information

CLINICAL POLICY Department: Medical Management Document Name: Pulmonary Arterial Hypertension Therapies

CLINICAL POLICY Department: Medical Management Document Name: Pulmonary Arterial Hypertension Therapies Page: 1 of 15 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis.

Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. March 2013 1. Pirfenidone is indicated in adults for the treatment of mild to moderate Idiopathic Pulmonary

More information

CADTH CANADIAN DRUG EXPERT REVIEW COMMITTEE FINAL RECOMMENDATION

CADTH CANADIAN DRUG EXPERT REVIEW COMMITTEE FINAL RECOMMENDATION CADTH CANADIAN DRUG EXPERT REVIEW COMMITTEE FINAL RECOMMENDATION RIOCIGUAT (Adempas Bayer HealthCare Inc.) Indication: Pulmonary Arterial Hypertension Recommendation: The CADTH Canadian Drug Expert Review

More information

Copyright 2012 Oregon State University. All Rights Reserved

Copyright 2012 Oregon State University. All Rights Reserved Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Clinical Commissioning Policy: Targeted Therapies for Pulmonary Hypertension Functional Class II. April 2013. Reference : NHSCB/A11/P/a

Clinical Commissioning Policy: Targeted Therapies for Pulmonary Hypertension Functional Class II. April 2013. Reference : NHSCB/A11/P/a Clinical Commissioning Policy: Targeted Therapies for Pulmonary Hypertension Functional Class II April 2013 Reference : NHS Commissioning Board Clinical Commissioning Policy: Amendment to National Policy

More information

SARCOIDOSIS. Signs and symptoms associated with specific organ involvement can include the following:

SARCOIDOSIS. Signs and symptoms associated with specific organ involvement can include the following: SARCOIDOSIS Sarcoidosis is a disease that occurs when areas of inflammation develop in different organs of the body. Very small clusters of inflammation, called granulomas, are seen with sarcoidosis. They

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Advanced Therapies for Pharmacological Treatment of Pulmonary Hypertension

Advanced Therapies for Pharmacological Treatment of Pulmonary Hypertension Advanced Therapies for Pharmacological Treatment of Pulmonary Hypertension Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,

More information

CADTH Therapeutic Review Report

CADTH Therapeutic Review Report Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Therapeutic Review Report March 2015 Drugs for Pulmonary Arterial Hypertension:

More information

Online supplements are not copyedited prior to posting.

Online supplements are not copyedited prior to posting. Functional Impact of a Spectrum of Interstitial Lung Abnormalities in Rheumatoid Arthritis Tracy J. Doyle, MD, MPH; Paul F. Dellaripa, MD; Kerri Batra, MD; Michelle L. Frits, BA; Christine K. Iannaccone,

More information

1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)

1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca) This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic

More information

The Global Alliance against Chronic Respiratory Diseases

The Global Alliance against Chronic Respiratory Diseases The Global Alliance against Chronic Respiratory Diseases Pulmonary hypertension Dr Marc Humbert What is the burden of pulmonary hypertension? The true burden of pulmonary hypertension is currently unknown

More information

Pulmonary Arterial Hypertension. Mark Rumbak, MD Professor of Medicine Morsani College of Medicine University of South Florida

Pulmonary Arterial Hypertension. Mark Rumbak, MD Professor of Medicine Morsani College of Medicine University of South Florida Pulmonary Arterial Hypertension Mark Rumbak, MD Professor of Medicine Morsani College of Medicine University of South Florida PAH Disease State Module Outline Background and definition Clinical classification

More information

A Review of Sitaxsentan Sodium in Patients with Pulmonary Arterial Hypertension

A Review of Sitaxsentan Sodium in Patients with Pulmonary Arterial Hypertension A Review of Sitaxsentan Sodium in Patients with Pulmonary Arterial Hypertension The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

More information

Chronic Thromboembolic Disease. Chronic Thromboembolic Disease Definition. Diagnosis Prevention Treatment Surgical Nonsurgical

Chronic Thromboembolic Disease. Chronic Thromboembolic Disease Definition. Diagnosis Prevention Treatment Surgical Nonsurgical Chronic Thromboembolic Disease Diagnosis Prevention Treatment Surgical Nonsurgical Chronic Thromboembolic Disease Definition Pulmonary Hypertension due to chronic thromboembolism 6 months post acute PE:

More information

James F. Kravec, M.D., F.A.C.P

James F. Kravec, M.D., F.A.C.P James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice

More information

Non-Invasive Risk Predictors in (Children with) Pulmonary Hypertension

Non-Invasive Risk Predictors in (Children with) Pulmonary Hypertension Ideal risk prognosticator Easy to acquire Non-Invasive Risk Predictors in (Children with) Pulmonary Hypertension Safe -- Non-invasive Robust Gerhard-Paul Diller Astrid Lammers Division of Adult Congenital

More information

Interpretation of Pulmonary Function Tests

Interpretation of Pulmonary Function Tests Interpretation of Pulmonary Function Tests Dr. Sally Osborne Cellular & Physiological Sciences University of British Columbia Room 3602, D.H Copp building 604 822-3421 sally.osborne@ubc.ca www.sallyosborne.com

More information

on behalf of the AUGMENT-HF Investigators

on behalf of the AUGMENT-HF Investigators One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas

More information

Pulmonary Arterial Hypertension (PAH) Agents 12/01/2009

Pulmonary Arterial Hypertension (PAH) Agents 12/01/2009 Pulmonary Arterial Hypertension (PAH) Agents 12/01/2009 Copyright 2006-2009 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this

More information

Position Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis

Position Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis BACKGROUND Position Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic and fatal disease characterised by

More information

Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational

Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study

More information

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Disclosures : None 77-year-old woman, mild dyspnea

More information

PULMONARY FUNCTION TESTS A Workshop on Simple Spirometry & Flow Volume Loops

PULMONARY FUNCTION TESTS A Workshop on Simple Spirometry & Flow Volume Loops PULMONARY FUNCTION TESTS A Workshop on Simple Spirometry & Flow Volume Loops YOU SHOULD READ THE FOLLOWING MATERIAL BEFORE Tuesday March 30 Interpretation of PFTs Learning Objectives 1. Specify the indications

More information

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4 Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.

More information

PAH has an incidence

PAH has an incidence Pulmonary Arterial Hypertension: A Serious Problem Pulmonary arterial hypertension (PAH) is a serious disease with significant morbidity and mortality and no cure. In this article, Dr. Porhownik and Dr.

More information

Recently approved drugs offer significant improvements for treatment options in pulmonary arterial hypertension

Recently approved drugs offer significant improvements for treatment options in pulmonary arterial hypertension DISEASE MANAGEMENT Recently approved drugs offer significant improvements for treatment options in pulmonary arterial hypertension Treatment of pulmonary arterial hypertension (PAH) Class I. PAH without

More information

April 2015 CALGARY ZONE CLINICAL REFERENCE PULMONARY CENTRAL ACCESS & TRIAGE

April 2015 CALGARY ZONE CLINICAL REFERENCE PULMONARY CENTRAL ACCESS & TRIAGE April 2015 CALGARY ZONE CLINICAL REFERENCE CENTRAL ACCESS & TRIAGE Introduction Pulmonary consulting services are organized through the Calgary Zone Pulmonary Central Access and Triage (PCAT). Working

More information

Summary Review for Regulatory Action

Summary Review for Regulatory Action Summary Review for Regulatory Action Date (electronic stamp) From Norman Stockbridge Subject Division Director Summary Review NDA/BLA # Supplement # NDA 21-290 Applicant Name Actelion Date of Submission

More information

Summary of the risk management plan (RMP) for Ofev (nintedanib)

Summary of the risk management plan (RMP) for Ofev (nintedanib) EMA/738120/2014 Summary of the risk management plan (RMP) for Ofev (nintedanib) This is a summary of the risk management plan (RMP) for Ofev, which details the measures to be taken in order to ensure that

More information

Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor)

Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor) EMA/662624/2015 Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor) This is a summary of the risk management plan (RMP) for Orkambi, which details the measures to be taken

More information

OVERVIEW FDA-APPROVED INDICATIONS

OVERVIEW FDA-APPROVED INDICATIONS Tufts Health Together Tufts Health Direct Pharmacy Medical Necessity Guidelines Pulmonary Hypertension Effective: December 9, 2014 Clinical documentation and prior authorization required Not covered Pharmacy

More information

Inpatient Heart Failure Management: Risks & Benefits

Inpatient Heart Failure Management: Risks & Benefits Inpatient Heart Failure Management: Risks & Benefits Dr. Kenneth L. Baughman Professor of Medicine Harvard Medical School Director, Advanced Heart Disease Section Brigham & Women's Hospital Harvard Medical

More information

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7

More information

Renovascular Hypertension

Renovascular Hypertension Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension

More information

Statement on Disability: Pulmonary Hypertension

Statement on Disability: Pulmonary Hypertension Statement on Disability: Pulmonary Hypertension Ronald J. Oudiz, MD and Robyn J. Barst, MD on behalf of Pulmonary Hypertension Association The Scientific Leadership Council of the Pulmonary Hypertension

More information

30 DAY COPD READMISSIONS AND PULMONARY REHAB

30 DAY COPD READMISSIONS AND PULMONARY REHAB 30 DAY COPD READMISSIONS AND PULMONARY REHAB Trina M. Limberg, Bs, RRT, FAARC, MAACVPR Director, Preventative Pulmonary and Rehabilitation Services UC San Diego Health System OVERVIEW The Impact of COPD

More information

Bronchodilators in COPD

Bronchodilators in COPD TSANZSRS Gold Coast 2015 Can average outcomes in COPD clinical trials guide treatment strategies? Long live the FEV1? Christine McDonald Dept of Respiratory and Sleep Medicine Austin Health Institute for

More information

ASK A DOC. Clinical Trial Update May 28, 2014. Welcome!

ASK A DOC. Clinical Trial Update May 28, 2014. Welcome! ASK A DOC Clinical Trial Update May 28, 2014 Welcome! ASK A DOC CLINICAL TRIAL UPDATE Dr. Gregory Cosgrove PFF Chief Medical Officer Dr. Kevin Flaherty Chairman Steering Committee PFF CCN and PFF Registry

More information

Cystic Lung Diseases. Melissa Price Gillian Lieberman, MD Advanced Radiology Clerkship Beth Israel Deaconess Medical Center November, 2008

Cystic Lung Diseases. Melissa Price Gillian Lieberman, MD Advanced Radiology Clerkship Beth Israel Deaconess Medical Center November, 2008 Cystic Lung Diseases Melissa Price Gillian Lieberman, MD Advanced Radiology Clerkship Beth Israel Deaconess Medical Center November, 2008 How do we define a cyst of the lung? Hansell DM, Bankier AA, MacMahon

More information

*Documentation of pretreatment results from right heart catheterization and PEA required, as applicable

*Documentation of pretreatment results from right heart catheterization and PEA required, as applicable DRUG POLICY BENEFIT APPLICATION Pulmonary Arterial Hypertension Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations

More information

Pulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled Therapeutic Class Review (TCR) March 30, 2015

Pulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled Therapeutic Class Review (TCR) March 30, 2015 Pulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled Therapeutic Class Review (TCR) March 30, 2015 No part of this publication may be reproduced or transmitted in any form or by any means, electronic

More information

Tests. Pulmonary Functions

Tests. Pulmonary Functions Pulmonary Functions Tests Static lung functions volumes Dynamic lung functions volume and velocity Dynamic Tests Velocity dependent on Airway resistance Resistance of lung tissue to change in shape Dynamic

More information

Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension

Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension Bing He, BSc;

More information

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1

More information

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension Chapter 27 Pulmonary Arterial Hypertension Gandharba Ray, L Ravi Kumar INTRODUCTION ABSTRACT Pulmonary arterial hypertension (PAH) is a syndrome resulting from decreased flow of blood in the pulmonary

More information

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital Mahidol University Journal of Pharmaceutical Sciences 008; 35(14): 81. Original Article Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

More information

Prevention of Acute COPD exacerbations

Prevention of Acute COPD exacerbations December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal

More information

Quiz 5 Heart Failure scores (n=163)

Quiz 5 Heart Failure scores (n=163) Quiz 5 Heart Failure summary statistics The correct answers to questions are indicated by *. Students were awarded 2 points for question #3 for either selecting spironolactone or eplerenone. However, the

More information

Defending the Rest Basics on Lung Cancer, Other Cancers and Asbestosis: Review of the B-Read and Pulmonary Function Testing

Defending the Rest Basics on Lung Cancer, Other Cancers and Asbestosis: Review of the B-Read and Pulmonary Function Testing Defending the Rest Basics on Lung Cancer, Other Cancers and Asbestosis: Review of the B-Read and Pulmonary Function Testing ASBESTOSIS November 2013 Bruce T. Bishop Lucy L. Brandon Willcox & Savage 440

More information

Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications

Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications Effective: January 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review

More information

Human Clinical Study for Free Testosterone & Muscle Mass Boosting

Human Clinical Study for Free Testosterone & Muscle Mass Boosting Human Clinical Study for Free Testosterone & Muscle Mass Boosting GE Nutrients, Inc. 920 E. Orangethorpe Avenue, Suite B Anaheim, California 92801, USA Phone: +1-714-870-8723 Fax: +1-732-875-0306 Contact

More information

Alpha-1 Antitrypsin Deficiency

Alpha-1 Antitrypsin Deficiency CORAM S VOLUME 5 Coram LLC is a leading national provider of home infusion services, including alternate site of care and specialty pharmacy distribution. 12450 East Arapahoe Road, Suite A, Centennial,

More information

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains

More information

SYNOPSIS. Risperidone: Clinical Study Report CR003274

SYNOPSIS. Risperidone: Clinical Study Report CR003274 SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:

More information

Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry

Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry CHEST Original Research PULMONARY VASCULAR DISEASE Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry Robyn J. Barst, MD ;

More information

Cytori Therapeutics NASDAQ: CYTX

Cytori Therapeutics NASDAQ: CYTX Cytori Therapeutics Scleroderma Informational Session January 2015 Restoring Lives 1 Forward-looking Statements This presentation contains certain forward-looking statements about Cytori Therapeutics,

More information

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent

More information

INTERSTITIAL LUNG DISEASE Paul F. Simonelli, MD, Ph.D.

INTERSTITIAL LUNG DISEASE Paul F. Simonelli, MD, Ph.D. INTERSTITIAL LUNG DISEASE Paul F. Simonelli, MD, Ph.D. Definition: Interstitial lung disease (ILD) refers to a broad range of conditions that have common clinical, physiological, and radiological features.

More information

Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital

Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI

More information

September 2008 [KT 168] Sub. Code: 2063 M.D. DEGREE EXAMINATION Branch XVII Tuberculosis and Respiratory Diseases NON-TUBERCULOSIS CHEST DISEASES Common to Part II Paper II - (Old /New/Revised Regulations)

More information

Medicare C/D Medical Coverage Policy

Medicare C/D Medical Coverage Policy Nebulizer Medications Origination: June 17, 2009 Review Date: October 21, 2015 Next Review: October, 2017 Medicare C/D Medical Coverage Policy DESCRIPTION Nebulizer medications are used to prevent and

More information

GT-020 Phase 1 Clinical Trial: Results of Second Cohort

GT-020 Phase 1 Clinical Trial: Results of Second Cohort GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic

More information

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational. Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,

More information

Spirometry Workshop for Primary Care Nurse Practitioners

Spirometry Workshop for Primary Care Nurse Practitioners Spirometry Workshop for Primary Care Nurse Practitioners Catherine Casey S. Jones PhD, RN, AE-C, ANP-C Certified Adult Nurse Practitioner Texas Pulmonary & Critical Care Consultants P.A. and Visiting Assistant

More information

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study

More information

STUDY DESCRIPTION Background information, study purpose and study rationale

STUDY DESCRIPTION Background information, study purpose and study rationale Sylvana M. Hidalgo, MD Originating Department: Pediatric Cardiology Submitting to: Medical Center Title: Single-Center Description of Clinical Presentation of Pulmonary Hypertension in Patients Also Diagnosed

More information

Cirrhosis and HCV. Jonathan Israel M.D.

Cirrhosis and HCV. Jonathan Israel M.D. Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment

More information

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and

More information

Ventilation Perfusion Relationships

Ventilation Perfusion Relationships Ventilation Perfusion Relationships VENTILATION PERFUSION RATIO Ideally, each alveolus in the lungs would receive the same amount of ventilation and pulmonary capillary blood flow (perfusion). In reality,

More information

Restrictive vs. Obstructive Disease (Dedicated to my good friend Joe Walsh)

Restrictive vs. Obstructive Disease (Dedicated to my good friend Joe Walsh) Restrictive vs. Obstructive Disease (Dedicated to my good friend Joe Walsh) The field of medicine has a long history of describing or classifying disease. Pulmonary disease is no different. Although there

More information

Department of Surgery

Department of Surgery What is emphysema? 2004 Regents of the University of Michigan Emphysema is a chronic disease of the lungs characterized by thinning and overexpansion of the lung-like blisters (bullae) in the lung tissue.

More information

Prof Geert M. Verleden UZ Gasthuisberg Leuven

Prof Geert M. Verleden UZ Gasthuisberg Leuven Prof Geert M. Verleden UZ Gasthuisberg Leuven Patients with chronic end-stage lung disease, such as COPD, CF, PAH, Pulmonary fibrosis Max 50-55 y for HLTx 60-65 y for LTx Failing medical treatment Or no

More information

HYPERTENSION ASSOCIATED WITH RENAL DISEASES

HYPERTENSION ASSOCIATED WITH RENAL DISEASES RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein

More information

Objectives. The ECG in Pulmonary and Congenital Heart Disease. Lead II P-Wave Amplitude during COPD Exacerbation and after Treatment (50 pts.

Objectives. The ECG in Pulmonary and Congenital Heart Disease. Lead II P-Wave Amplitude during COPD Exacerbation and after Treatment (50 pts. The ECG in Pulmonary and Congenital Heart Disease Gabriel Gregoratos, MD Objectives Review the pathophysiology and ECG signs of pulmonary dysfunction Review the ECG findings in patients with: COPD (chronic

More information

Phase: IV. Study Period: 20 Jan. 2006-17 Sep. 2008

Phase: IV. Study Period: 20 Jan. 2006-17 Sep. 2008 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information